# Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468

**Authors:** Divya B Kenchappa, Olga Korolkova, Nobelle Sakwe, Peace Odiase, Michael G. Izban, Amos Sakwe, Josiah Ochieng

PMC · DOI: 10.26502/fjppr.0103 · 2025-03-21

## TL;DR

This study shows that fetuin-A increases tumor growth and invasion in a type of breast cancer by interacting with TLR4, suggesting a new target for treatment.

## Contribution

The study identifies fetuin-A-TLR4 signaling as a novel driver of growth and invasion in basal-like triple negative breast cancer.

## Key findings

- Fetuin-A overexpression enhances invasive potential and TLR4 expression in MDA-MB-468 cells.
- TLR4 inhibition with CLI-095 abrogates fetuin-A-mediated growth and invasion.
- Fetuin-A-TLR4 signaling is critical for tumor progression in triple negative breast cancer.

## Abstract

The present studies were undertaken to address the innovative role of fetuin-A in the growth and invasion potential in a triple negative breast cancer (TNBC) cell line, MDA-MB-468. Basal like TNBC that express high levels of ectopic fetuin-A have poorer prognosis for the patients compared to those that express low levels of the protein. We overexpressed fetuin-A in MDA-MB-468 and then determined the invasive potential of fetuin-A overexpressing cells vs controls transfected with empty vector. We also determined the adhesion and growth potential of the cells in the presence of only fetuin-A in serum free medium and also in complete medium. Our data suggest that fetuin-A overexpression significantly enhances the invasive potential of the cells and also the expression of Toll like receptor 4 (TLR4) on these cells. More importantly, the cells rely on fetuin-A-TLR4 signaling network for growth and invasion because the specific TLR4 inhibitor CLI-095 (resatorvid) abrogates fetuin-A mediated growth and invasion. Taken together, the data suggest that fetuin-A-TLR4 signaling network plays a significant role in the growth and invasion potential of TNBC.

## Linked entities

- **Proteins:** AHSG (alpha 2-HS glycoprotein), TLR4 (toll like receptor 4)
- **Chemicals:** CLI-095 (PubChem CID 11703255), resatorvid (PubChem CID 11703255)
- **Diseases:** triple negative breast cancer (MONDO:0005494), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** AHSG (alpha 2-HS glycoprotein) [NCBI Gene 197] {aka A2HS, AHS, APMR1, FETUA, HSGA}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}
- **Diseases:** TNBC (MESH:D064726), Tumor (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MDA-MB-468 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0419)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11928157/full.md

---
Source: https://tomesphere.com/paper/PMC11928157